Pfizer (PFE Quick QuotePFE - Free Report) reported $15.03 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 2.6%. EPS of $0.77 for the same period compares to $0.78 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $14.45 billion, representing a surprise of +4.04%. The company delivered an EPS surprise of +13.24%, with the consensus EPS estimate being $0.68.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Specialty Care- Cibinqo- United States: $34 million compared to the $30 million average estimate based on two analysts. The reported number represents a change of +41.7% year over year.
• Revenues- Primary Care- Comirnaty- Total International: $223 million versus $165.71 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.8% change.
• Revenues- Specialty Care- United States: $1.68 billion versus the two-analyst average estimate of $1.5 billion. The reported number represents a year-over-year change of -19.5%.
• Revenues- Specialty Care- Total International: $1.68 billion versus $1.7 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -27% change.
• Revenues- Oncology- Ibrance- Worldwide: $1.06 billion versus the two-analyst average estimate of $1.05 billion. The reported number represents a year-over-year change of +0.9%.
• Revenues- Specialty Care- Xeljanz- Worldwide: $251 million versus $227.94 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -22.1% change.
• Revenues- Specialty Care- Inflectra- Worldwide: $171 million versus the two-analyst average estimate of $108.59 million. The reported number represents a year-over-year change of +23%.
• Revenues- Primary Care- Eliquis- Worldwide: $2.43 billion versus the two-analyst average estimate of $1.98 billion. The reported number represents a year-over-year change of +21.1%.
• Revenues- Pfizer CentreOne- Worldwide: $373 million versus the two-analyst average estimate of $326.17 million. The reported number represents a year-over-year change of +13.7%.
• Revenues- Pfizer Biopharma- Worldwide: $14.66 billion compared to the $14.09 billion average estimate based on two analysts. The reported number represents a change of +2.5% year over year.
• Revenues- Specialty Care- Vyndaqel family- Worldwide: $1.76 billion versus the two-analyst average estimate of $1.75 billion. The reported number represents a year-over-year change of +9.1%.
• Revenues- Primary Care- Comirnaty- Worldwide: $261 million versus $278.14 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -31.5% change.

View all Key Company Metrics for Pfizer here>>>

Shares of Pfizer have returned +5.5% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.